Trial Watch: Chemotherapy with immunogenic cell death inducers

Mostrar otras versiones (2)

Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs, including conventional chemotherapeutics as well as targeted anticancer agents, originates (at least in part) from their ability to elicit a novel or reinstate a pre-existing tumor-specific immune response. One o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacchelli, Erika, Aranda, Fernando, Eggermont, Alexander, Galon, Jérôme, Sautès-Fridman, Catherine, Cremer, Isabelle, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008470/
https://www.ncbi.nlm.nih.gov/pubmed/24800173
http://dx.doi.org/10.4161/onci.27878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008470/
https://www.ncbi.nlm.nih.gov/pubmed/24800173
http://dx.doi.org/10.4161/onci.27878

Ejemplares similares